Alpha 1 Global

Our mission is to develop a collaborative global network of Alpha-1 patient leaders, physicians, and researchers, to increase awareness, detection, and access to care for Alphas around the world.


Gene-silencing Therapy (RNAi) is on the Move

“The recent announcements by Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals are excellent news for our patients. Both companies are developing therapies for the liver by ‘silencing’ …

Read More

Antibacterial Drug for Rare Lung Disease Gets Approved

The U.S. Food and Drug Administration (FDA) approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a …

Read More

European Alpha-1 Research Collaboration – EARCO

A European Alpha-1 Research Collaboration (EARCO) has been formed to build a network of researchers and clinicians across Europe to improve research and treatment of …

Read More

Peg Iverson joins the Board of Directors

The Alpha-1 Foundation announces that Peg Iverson was named as member of its Board of Directors. Peg is very involved with the Alpha-1 community and …

Read More

Small Advances of Great Achievement in AATD Research Throughout Spain

September 2018, Valencia, Spain The following report is submitted by Dr. Francisco Dasí (PhD) as a summary of the different  lines of AATD research which …

Read More

Alfas en Camino: A Life Changing Journey

Over the centuries, millions of pilgrims have come together on the roads of Santiago which turned the route into a global symbol of effort, friendship, …

Read More

New Advances in Gene Therapies for Rare Diseases

The U.S. Food and Drug Administration (FDA) recently approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis …

Read More

72 Join Forces for the 1st ‘Alfas en Camino 2018’ Awareness Trek

On the morning of Sunday, 27 August, the village of Sarria was the starting point of the group Alfas en Camino pilgrimage to Santiago of patients and …

Read More

Alpha-1 Foundation Leadership Transition

The Alpha-1 Foundation Board of Directors is pleased to announce that Miriam O’Day has been named as interim CEO of the Alpha-1 Foundation. Ms. O’Day …

Read More

Orphan Drug Designation Granted to Bronchiolitis Obliterans Treatment

Onspira Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to its investigational product, OSP-101, for the treatment of Bronchiolitis …

Read More

Alpha-1 Around The Globe

Click on the country flags below to learn more about country specific contact and general information, access to care, and available resources

Join Our Newsletter

Subscribe to stay in touch with the latest in Alpha-1 Global